Matthew Downham PhD

Dr. Downham studied a Bachelor of Sciences degree (with honors) in industrial biology at London South Bank Polytechnic (UK) which included a placement with Boehringer Mannheim (DE). He then completed a Ph.D. in biochemical engineering (Birmingham University, UK), a post-doctoral research fellowship - bio-molecular sciences (Liverpool John Moores University, UK), and a post-graduate certificate in further/higher education (Bolton Institute, UK). He joined the biopharmaceutical industry in 1997 and has worked for Protherics (UK), Bavarian Nordic & Morphosys (DE), Novartis Vaccines & Diagnostics (IT) & AstraZeneca (UK).

Dr. Downham worked on the preclinical and early clinical development of a vaccine, antibody, or enzyme therapies for infectious, hypertension, inflammatory, and oncology indications. He was a European Registered Toxicologist (2010-18); Chair, Vaccines Europe Influenza working group (2017-20); Treasurer, International Federation of Pharmaceutical Manufacturers & Associations Influenza Vaccine Supply task force (2017-20); Vice-Chair, IFPMA Convention on Biological Diversity working group (2018-20).

Dr. Downham has also co-authored 29 publications/abstracts and 3 international patents and in January 2021, joined the Coalition for Epidemic Preparedness Innovations (UK) as the Sustainable Manufacturing Lead. Key Relevant Information: BSc Hons Industrial Biology (London South Bank Polytechnic, UK & Boehringer Mannheim, DE), Ph.D. Biochemical Engineering (Birmingham University, UK), PGCE (Bolton Institute, UK), post-doctoral research fellowship – biomolecular sciences (Liverpool John Moores University, UK) and an EU Registered Toxicologist (Royal Society of Biology UK, 2010-‘18) 25 years international biopharmaceutical industry: Boehringer Mannheim (DE), Protherics (UK), Bavarian Nordic & Morphosys (DE), Novartis Vaccines & Diagnostics (IT), AstraZeneca (UK).